CG Oncology will continue to strive for further improved access and diversity across our clinical development program.
We do this by actively looking to include diverse populations in our clinical studies and by having clinical sites in areas where there is a range of racial, socio-economic and environmental conditions. We also include some academic hospitals, VA (Veterans Administration) and many community urology practices sites in our clinical studies, reflecting the wide range of urology sites where patients receive their care.
At CG Oncology we are working with a diverse group of investigators including one study with a mainly female steering committee.
We have also provided support for reimbursement to patients who participate in clinical studies, which we hope will lead to more diversity in the social-economic groups that are represented in CG Oncology studies.
The Importance of Diversity & Inclusion in Clinical Trials
People may experience the same disease differently. It’s essential that clinical trials include people with a variety of lived experiences and living conditions, as well as characteristics like race and ethnicity, age, sex, and sexual orientation, so that all communities can benefit from scientific advances.
Factors that can influence the risk and likelihood of developing a disease, experiencing a long-term health outcome, and responding to treatment include (but are not limited to):
- Age
- Biological sex
- Pregnancy status
- Life experiences (negatives, such as psychosocial stress and lack of basic resources, or positives, such as educational and employment opportunities)
- Variations in Health behaviors (e.g., adequate sleep, obtaining recommended preventive services, physical activity, healthy eating)
- Environmental conditions (e.g., pollution, access to health care or healthy foods, neighborhood segregation)
- Genetic variation and geographic ancestry
- Underlying medical problems or presence of comorbidities (i.e., additional diseases or conditions)
